注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Annexon Inc是一家临床阶段的生物制药公司。该公司致力于为患有严重补体介导的自身免疫性疾病、神经退行性疾病和眼科疾病的患者开发补体药物。它的产品线包括三个临床阶段的资产,跨越三个治疗专营权:自身免疫、神经退行性病变和眼科。其主要候选基因ANX005是一种单克隆抗体,可用于多种自身免疫适应症的静脉注射。ANX005正在接受治疗格林-巴利综合征患者的II/III期临床试验和治疗温热性自身免疫性溶血性贫血患者的II期试验的评估。ANX009临床候选者是一种抗原结合片段的皮下制剂,在一期试验中进行评估。该公司还在开发ANX005,该产品正在亨廷顿病和肌萎缩侧索硬化症的II期试验中。该公司的ANX007计划是一个由Fab制定的计划。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Douglas Love | 54 | 2014 | CEO, President & Director |
Thomas G. Wiggans | 70 | 2017 | Independent Chairman |
Muneer Ahmad Satter | 61 | 2014 | Independent Director |
Bettina M. Cockroft | 55 | 2022 | Independent Director |
William H. Carson | 64 | 2021 | Independent Director |
Jung E. Choi | 54 | 2020 | Independent Director |
Stephen L. Hauser | - | - | Member of Scientific Advisory Board |
David M. Holtzman | - | - | Member of Scientific Advisory Board |
P. Hugh Willison | - | - | Member of Scientific Advisory Board |
Beth Stevens | - | - | Member of Scientific Advisory Board |
William D. Waddill | 67 | 2021 | Independent Director |
Thomas P. Maniatis | 81 | - | Member of Scientific Advisory Board |
Jeffrey Goldberg | - | - | Member of Scientific Advisory Board |
Ted Yednock | 66 | 2013 | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核